Trusted News Discovery Since 2008
One News Page
One News Page > Business News > Zelira Therapeutics fully enrols cannabis clinical trial

Zelira Therapeutics fully enrols cannabis clinical trial

Proactive Investors Wednesday, 26 February 2020
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) has now fully enrolled its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment. The trial is evaluating the safety and tolerability when dosing patients with a whole plant extract. Secondary outcomes include pharmacokinetics and the effects on pain, mood, sleep and opioid use over the duration of the trail. No serious adverse events from dosing patients have been reported to date. Dosing is expected to be completed by April 2020 with the final report to be provided by mid-2020. Trial being done with Emerald Clinics Ltd (ASX:EMD) Zelira’s managing director Dr Richard Hopkins said: “We are delighted to have achieved full enrolment, which represents a major milestone for the trial. “We’re also pleased for the opportunity to expand our partnership with Emerald Clinics by bringing them on as a second site. “We have been impressed by their ability to complement the efforts of the St Vincent team by rapidly screening and enrolling eligible patients into trial.” Recent placement secures $4.6 million Zelira recently accepted applications from overseas investors for an additional 1.08 million shares as part of a share placement. Following the acceptance of oversubscriptions, the placement’s total size increased to $4.64 million. The funds will be used to accelerate Zelira’s plans to launch multiple products into global markets in 2020 and to advance its clinical programs, including its Insomnia and Opioid Sparing trials, which are due to read-out in the first half of this year. A global therapeutic medicinal cannabis company Zelira is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest-growing cannabis markets. The company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. It is currently undertaking: Human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the USA; and Pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.  

You Might Like

Recent related videos from verified sources

Tampa clinical research facility sheds light on clinical trials for coronavirus [Video]

Tampa clinical research facility sheds light on clinical trials for coronavirus

ForCare Medical Group is on the front lines doing clinical research on a variety of autoimmune diseases. Story:

Credit: ABC Action News     Duration: 00:56Published
US Begins First Human Trial of Coronavirus Vaccine [Video]

US Begins First Human Trial of Coronavirus Vaccine

US Begins First Human Trial of Coronavirus Vaccine The first human trial to evaluate a candidate vaccine against the new coronavirus has begun in Seattle. The vaccine, called mRNA-1273, was developed..

Credit: Wibbitz Top Stories     Duration: 01:11Published

Recent related news from verified sources

UAB will take part in global clinical trial for COVID-19 treatment

UAB will take part in a National Institutes of Health (NIH)-sponsored global clinical trial to evaluate the safety and efficacy of therapeutic agents in...
bizjournals Also reported by •Proactive InvestorsRTTNews

Humanigen poised to partner with leading contract research organization on Phase III trial to tackle deadly coronavirus

Humanigen Inc (OTCMKTS:HGEN) shares rose on Monday as it announced that it will partner with contract research organization, CTI Clinical Trial and Consulting...
Proactive Investors

Tweets about this

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2020 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.